Anti-Human Bcl-2 Modifying Factor (CT) (BMF)

Home/Primary Monoclonal Antibodies/Apoptosis & Cell Biology/Anti-Human Bcl-2 Modifying Factor (CT) (BMF)

Pricing & Details

Product No.B382
Protein
BMF
Formats AvailableView All
Product Type
Polyclonal Antibody
Alternate Names
Bcl-2 Modifying Factor
Applications
IHC FFPE
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
B382-20ug
20 µg
$195.00
In stock
Max:
Min: 1
Step: 1
B382-0.1 mg
0.1 mg
$397.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Data

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Rabbit
Immunogen
PN:B494
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Human Bcl-2 Modifying Factor (BMF) recognizes and epitope near the C-terminus of Human BMF. This polyclonal antibody was purified using affinity chromatography.
Background
Apoptosis is related to many diseases and development. Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3-only proteins, including Bad, Bid, Bik, Hrk, Bim, Noxa, and PUMA, form a growing subclass of the Bcl-2 family. A novel BH3-only protein was recently identified in human and mouse and designated Bmf (for Bcl-2-modifing factor).1 The BH3 domain in Bmf is required both for binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the dynein light chain 2 (DLC2) component of the myosin V motors and is sequestered by the cell's actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptotic program.1,2 Bmf is constitutively expressed in many tissues.1,2

Antigen Details

Protein
PubMed

References & Citations

1. Puthalakath, H. et al. (2001) Science. 293(5536):1829-32.
2. Hunt, A. and Evan, G. (2001) Science. 293(5536):1784-5.
IHC
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok